Abeona Therapeutics (ABEO) Cash & Current Investments (2010 - 2026)

Abeona Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $168.3 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 99.95% year-over-year to $168.3 million; the TTM figure through Mar 2026 stood at $168.3 million (up 99.95% YoY), while the FY2025 annual figure was $191.4 million, up 95.19% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $168.3 million, down from $191.4 million in the prior quarter.
• The five-year high for Cash & Current Investments was $225.5 million in Q2 2025, with the low at $16.9 million in Q1 2022.
• The 5-year median for Cash & Current Investments is $54.1 million (2023), against an average of $88.6 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments tumbled 80.76% in 2022, then jumped 197.75% in 2023.
• Abeona Therapeutics' Cash & Current Investments stood at $52.5 million in 2022, then increased by 0.15% to $52.6 million in 2023, then soared by 86.55% to $98.1 million in 2024, then surged by 95.19% to $191.4 million in 2025, then retreated by 12.09% to $168.3 million in 2026.
• Business Quant data shows ABEO's Cash & Current Investments at $168.3 million in Q1 2026, $191.4 million in Q4 2025, and $207.5 million in Q3 2025.